Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06252649 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

Name: Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation — clinical trial record (NCT06252649)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: CodeBreaK 301

StatusRecruiting

PhasePhase 3

SponsorAmgen

Started2024-07-17

View on ClinicalTrials.gov ↗

The aim of this study is to compare progression free survival (PFS) in treatment-naïve participants with KRAS p.G12C mutated metastatic colorectal cancer (mCRC) receiving sotorasib, panitumumab and FOLFIRI vs FOLFIRI with or without bevacizumab-awwb.

Amendment history 3 changes detected by DataLookout

2026-06-11

Trial sites expanded: 286 → 290 locations

2026-06-11

Primary completion pushed: 2028-01-31 → 2028-09-25

2026-06-11

Completion pushed: 2031-08-31 → 2032-04-25

Trial Details

NCT Number	NCT06252649
Lead Sponsor	Amgen
Conditions	Metastatic Colorectal Cancer
Enrollment	450 participants
Start Date	2024-07-17
Primary Completion	2028-09-25 (estimated)
Study Completion	2032-04-25 (estimated)
Updated on ClinicalTrials.gov	2026-09-03